# A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

> **NCT01196208** · — · NO_LONGER_AVAILABLE · sponsor: **Seagen Inc.**

## Conditions studied

- Disease, Hodgkin
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell, Cutaneous

## Interventions

- **DRUG:** brentuximab vedotin

## Key facts

- **NCT ID:** NCT01196208
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01196208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01196208, "A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01196208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*